This presentation will include a review of the HALAVEN’s updated indication and mechanism of action. HALAVEN has been approved as a treatment choice for metastatic breast cancer and advanced liposarcoma. HALAVEN acts on the tumor through a culmination of its tubulin based antimitotic action and biological effects on tumor vascularization and microenvironment.
Vermont law prohibits, Minnesota law restricts, and Department of Veterans Affairs and Department of Defense policy prohibits Eisai from offering meals at speaker events to certain health care professionals. If you are licensed in either of those states, or employed by either agency, Eisai regrets that due to these restrictions, we will not be able to offer a meal in conjunction with this event. Additionally, Eisai is required by Massachusetts, Vermont, Washington DC, and the Federal Physician Payment Sunshine Act to disclose certain value transfers, eg, meals, provided to certain health care professionals. If you have questions regarding how Eisai tracks and reports this information, please contact Eisai at 1-855-643-4328.
